Inhibition of protein tyrosine phosphatase non-receptor type 2 by PTP inhibitor XIX: Its role as a multiphosphatase inhibitor
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. In this study, PTP inhibitor XIX, an inhibitor of CD45 and PTEN, was investigated whether it inhibits other PTPs. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) was selectively inhibited by the inhibitor in a competitive manner. Drug affinity responsive target stability (DARTS) analysis showed that the inhibitor induces conformational changes in PTPN2. Phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) at Tyr-705, a crucial site for STAT3 activation and target site of PTPN2, decreased upon exposure to the inhibitor. Our results suggest that PTP inhibitor XIX might be considered as an effective regulator of PTPN2 for treating diseases related to PTPN2.
Abstract
Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. In this study, PTP inhibitor XIX, an inhibitor of CD45 and PTEN, was investigated whether it inhibits other PTPs. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) was selectively inhibited by the inhibitor in a competitive manner. Drug affinity responsive target stability (DARTS) analysis showed that the inhibitor induces conformational changes in PTPN2. Phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) at Tyr-705, a crucial site for STAT3 activation and target site of PTPN2, decreased upon exposure to the inhibitor. Our results suggest that PTP inhibitor XIX might be considered as an effective regulator of PTPN2 for treating diseases related to PTPN2.
참고문헌 (20)
- Hunter T, "Signaling—2000 and Beyond", Cell, 100, pp.113~127 (2000)
- Ciesla J, "Phosphorylation of basic amino acid residues in proteins: important but easily missed", Acta Biochim Pol, 58, pp.137~148 (2011)
- Barford D, "The structure and mechanism of protein phosphatases: insights into catalysis and regulation", Annu Rev Biophys Biomol Struct, 27, pp.133~164 (1998)
- Alonso A, "Protein tyrosine phosphatases in the human genome", Cell, 117, pp.699~711 (2004)
- Bononi A, "Protein kinases and phosphatases in the control of cell fate", Enzyme Res, 2011, pp.329098~ (2011)
- Heneberg P, "Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs", Curr Med Chem, 16, pp.706~733 (2009)
- Zhang ZY, "Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development", Annu Rev Pharmacol Toxicol, 42, pp.209~234 (2002)
- Scott LM, "Targeting protein tyrosine phosphatases for anticancer drug discovery", Curr Pharm Des, 16, pp.1843~1862 (2010)
- Urbanek RA, "Potent reversible inhibitors of the protein tyrosine phosphatase CD45", J Med Chem, 44, pp.1777~1793 (2001)
- Spinelli L, "PTEN inhibitors: an evaluation of current compounds", Adv Biol Regul, 57, pp.102~111 (2015)
- Li Y, "Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia", Blood, 113, pp.4930~4941 (2009)
- Rosivatz E, "A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN)", ACS Chem Biol, 1, pp.780~790 (2006)
- Chang J, "Advances in identification and validation of protein targets of natural products without chemical modification", Nat Prod Rep, 33, pp.719~730 (2016)
- García-Carreño FL, "Protease inhibition in theory and practice", Biotechnology Education, 3, pp.145~150 (1992)
- Lee H, "Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation", J Biol Chem, 290, pp.13~24 (2015)
- Kok CH, "Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients", Leukemia, 28, pp.702~705 (2014)
- Yu W, "PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3", Dis Markets, 32, pp.83~91 (2012)
- Wu Z, "PTPN2 rs1893217 single-nucleotide polymorphism is associated with risk of Behcet's disease in a Chinese Han population", Clin Exp Rheumatol, 32, pp.S20~S26 (2014)
- Tierno MB, "Development and optimization of high-throughput in vitro protein phosphatase screening assays", Nat Protoc, 2, pp.1134~1144 (2007)
- Shi Z, "Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects", Chembiochem, 8, pp.2092~2099 (2007)